I don’t see why not since they already do that, both Pfizer and Moderna already have targeted multiple regions on the spike protein, presumably they also modele

I don’t see why not since they already do that, both Pfizer and Moderna already have targeted multiple regions on the spike protein, presumably they also modeled them to optimize for antibody interaction and stability by taking regions that are less likely to mutate without loss of function. If you reach out the limit of what you can encode in a single mRNA payload you can add additional payloads to a single dose or spread them across multiple doses. Engineered viral vectors also can do similar things and also have a base pair limit so the solution would be similar.